Position Paper of the Polish Expert Group on the Use of Pitavastatin in the Treatment of Lipid Disorders in Poland Endorsed by the Polish Lipid Association.

LDL-C is the basic lipid parameter that should be measured to determine CV risk and determines the aim and LLT target. LLT improves cardiovascular prognosis and prolongs life in both primary and secondary cardiovascular prevention. Despite the availability of effective lipid-lowering drugs and solid data on their beneficial effects, the level of LDL-C control is highly insufficient. This is related to physician inertia and patients' fear of side effects. The development of lipidology has made drugs available with a good safety profile and enabling personalisation of therapy. Pitavastatin, the third most potent statin, is characterised by a lower risk of muscle complications and NOD due to its being metabolised differently. Thus, pitavastatin is a good therapeutic option in patients at high risk of diabetes or with existing diabetes, and in patients at cardiovascular risk. This Position Paper indicates the place of using pitavastatin in the treatment of lipid disorders.